lobbying_filings_raw: 16509c1e-9fb5-4cab-b642-d23246d53c62
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | is_amendment | is_no_activity | is_termination | raw_json | registrant_state | registrant_country | registrant_house_id | client_state | client_ppb_state | client_country | client_ppb_country | client_general_description | client_government_entity | affiliated_org_count | client_entity_id | client_government_unit_id | client_match_method | client_match_confidence | income_amount | expense_amount |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16509c1e-9fb5-4cab-b642-d23246d53c62 | 3T | 400432093 | CAPITOL LEGISLATIVE STRATEGIES LLC | 190838 | EMERGENT BIOSOLUTIONS INC. | 2017 | third_quarter | 2017-10-11T12:54:30.637000-04:00 | 0 | 0 | 1 | {"url": "https://lda.senate.gov/api/v1/filings/16509c1e-9fb5-4cab-b642-d23246d53c62/", "filing_uuid": "16509c1e-9fb5-4cab-b642-d23246d53c62", "filing_type": "3T", "filing_type_display": "3rd Quarter - Termination", "filing_year": 2017, "filing_period": "third_quarter", "filing_period_display": "3rd Quarter (July 1 - Sep 30)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/16509c1e-9fb5-4cab-b642-d23246d53c62/print/", "filing_document_content_type": "text/html", "income": null, "expenses": null, "expenses_method": null, "expenses_method_display": null, "posted_by_name": "Charles J. Mellody", "dt_posted": "2017-10-11T12:54:30.637000-04:00", "termination_date": "2017-09-01", "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "655 15th Street, NW", "registrant_address_2": "Suite 425", "registrant_different_address": true, "registrant_city": "Washington", "registrant_state": "DC", "registrant_zip": "20005", "registrant": {"id": 400432093, "url": "https://lda.senate.gov/api/v1/registrants/400432093/", "house_registrant_id": null, "name": "CAPITOL LEGISLATIVE STRATEGIES LLC", "description": "government affairs consulting, strategy, and representation", "address_1": "35192 Muirfield Cir", "address_2": null, "address_3": null, "address_4": null, "city": "Dagsboro", "state": "DE", "state_display": "Delaware", "zip": "19939", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "CHARLES MELLODY", "contact_telephone": "+1 202-352-5158", "dt_updated": "2026-01-30T11:42:01.741056-05:00"}, "client": {"id": 190838, "url": "https://lda.senate.gov/api/v1/clients/190838/", "client_id": 12, "name": "EMERGENT BIOSOLUTIONS INC.", "general_description": "A biopharmaceutical company focused on developing and manufacturing vaccines.", "client_government_entity": false, "client_self_select": false, "state": "MD", "state_display": "Maryland", "country": "US", "country_display": "United States of America", "ppb_state": null, "ppb_state_display": null, "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2009-02-01"}, "lobbying_activities": [{"general_issue_code": "DEF", "general_issue_code_display": "Defense", "description": "Issues related to national biodefense and chemical decontamination.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 48894, "prefix": "mr", "prefix_display": "MR.", "first_name": "CHARLES", "nickname": null, "middle_name": "J", "last_name": "MELLODY", "suffix": null, "suffix_display": null}, "covered_position": "Assistant to the Chairman, Ways and Means", "new": false}, {"lobbyist": {"id": 55846, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "JENNA", "nickname": null, "middle_name": "MORGAN", "last_name": "HAMILTON", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "HCR", "general_issue_code_display": "Health Issues", "description": "DHHS provisions related to development, stockpiling and acquisition of biodefense vaccines.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 48894, "prefix": "mr", "prefix_display": "MR.", "first_name": "CHARLES", "nickname": null, "middle_name": "J", "last_name": "MELLODY", "suffix": null, "suffix_display": null}, "covered_position": "Assistant to the Chairman, Ways and Means", "new": false}, {"lobbyist": {"id": 55846, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "JENNA", "nickname": null, "middle_name": "MORGAN", "last_name": "HAMILTON", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "HOM", "general_issue_code_display": "Homeland Security", "description": "Federal budget and appropriations provisions related to development, acquisition and stockpiling of biodefense vaccines. Implementation of Biomedical Advanced Research and Development Authority (BARDA) and Project BioShield related to stockpiling of defense vaccines.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 48894, "prefix": "mr", "prefix_display": "MR.", "first_name": "CHARLES", "nickname": null, "middle_name": "J", "last_name": "MELLODY", "suffix": null, "suffix_display": null}, "covered_position": "Assistant to the Chairman, Ways and Means", "new": false}, {"lobbyist": {"id": 55846, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "JENNA", "nickname": null, "middle_name": "MORGAN", "last_name": "HAMILTON", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} | DE | US | MD | US | US | A biopharmaceutical company focused on developing and manufacturing vaccines. | 0 | 0 |